LYTIR

Company · GRCE

Grace Therapeutics, Inc.

Nasdaq's symbol directory lists GRCE on Nasdaq as “Grace Therapeutics, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 22 occasions ($807K); 3 filings by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $807K in total; Insider sales: $0 in total.Aug: Insider purchases $24KSep: Insider purchases $294KOct: Insider purchases $456KNov: Insider purchases $33KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $807KInsider sales below: $0
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Opaleye Management Inc. bought on 21 days latest Nov 5, 2026 bought $593K
  2. Prashant Kohli, Chief Executive Officer bought on 1 day latest Sep 9, 2026 bought $214K
Every trade (22)
  1. BUYOpaleye Management Inc. bought Nov 5, 2026 3,087 shares filing $5K
  2. BUYOpaleye Management Inc. bought Nov 4, 2026 5,027 shares filing $9K
  3. BUYOpaleye Management Inc. bought Nov 3, 2026 10,328 shares filing $18K
  4. BUYOpaleye Management Inc. bought Oct 26, 2026 66,411 shares filing $117K
  5. BUYOpaleye Management Inc. bought Oct 22, 2026 21,390 shares filing $41K
  6. BUYOpaleye Management Inc. bought Oct 19, 2026 4,256 shares filing $8K
  7. BUYOpaleye Management Inc. bought Oct 16, 2026 36,347 shares filing $69K
  8. BUYOpaleye Management Inc. bought Oct 15, 2026 23,485 shares filing $46K
  9. BUYOpaleye Management Inc. bought Oct 14, 2026 11,233 shares filing $22K
  10. BUYOpaleye Management Inc. bought Oct 12, 2026 7,215 shares filing $15K
  11. BUYOpaleye Management Inc. bought Oct 9, 2026 5,340 shares filing $11K
  12. BUYOpaleye Management Inc. bought Oct 8, 2026 2,077 shares filing $4K
  13. BUYOpaleye Management Inc. bought Oct 5, 2026 1,694 shares filing $3K
  14. BUYOpaleye Management Inc. bought Oct 2, 2026 20,000 shares filing $41K
  15. BUYOpaleye Management Inc. bought Oct 1, 2026 38,796 shares filing $79K
  16. BUYOpaleye Management Inc. bought Sep 29, 2026 7,849 shares filing $16K
  17. BUYOpaleye Management Inc. bought Sep 23, 2026 5,318 shares filing $11K
  18. BUYOpaleye Management Inc. bought Sep 21, 2026 9,771 shares filing $21K
  19. BUYPrashant Kohli, Chief Executive Officer bought Sep 9, 2026 100,000 shares filing $214K
  20. BUYOpaleye Management Inc. bought Sep 9, 2026 5,836 shares filing $12K
  21. BUYOpaleye Management Inc. bought Sep 8, 2026 9,393 shares filing $20K
  22. BUYOpaleye Management Inc. bought Aug 14, 2026 11,608 shares filing $24K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. ADAR1 Capital Management, LLC filed Aug 14, 2026 Schedule 13G/A passive filing 9.9%
  2. Nantahala Capital Management, LLC filed Aug 14, 2026 Schedule 13G/A passive filing 6.75%
  3. Opaleye Management Inc. filed Aug 7, 2026 Schedule 13G passive 2,748,392 shares filing 13.07%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Submission of matters to a vote of security holders filing Sep 18, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.